from HLA-sensitized renal transplant candidates than in non-sensitized candidates 22 and have been reported to correlate with AMR in heart transplantation 23 . In a prospective multicentre trial that used peripheral blood endothelial cell precursors for antibody detection, kidney transplant recipients with pretransplant AECA had increased episodes of early acute rejection and higher creatinine levels than those without AECA 24 . However, a comparable study of 71 living donor renal transplants showed that pretransplantation AECA were not associated with acute rejection or with inferior renal graft function, suggesting that organs from deceased donors might exhibit higher levels of non-HLA antibody ligands than those from living donors 25 . Interestingly, many of the renal rejections that were reported to be associated with AECA were negative for the complement degradation product C4d and were graded as cellular rejection. Although AECA have been shown to activate complement resulting in C4d or C3d deposition in the graft in patients 26 and in animal models 27, 28 , others have reported the absence of C4d staining in biopsy samples from recipients with AECA 17, 19, 29, 30 . This discrepancy could result from the fact that endothelial-cell-reactive antibodies are enriched for noncomplement-fixing subclasses IgG2 and IgG4 (REF. 31 ). Even in the absence of complement deposition, however, AECA + biopsy samples exhibit histologic findings consistent with AMR, including glomerulitis, transplant glomerulopathy, focal interstitial haemorrhage, focal capillary thrombosis, and margination of neutrophils, monocytes and macrophages in the peritubular capillaries 29, 30, 32, 33 . The specificity of the autoantibodies developed during the immune response to the allograft is diverse. Using a proteomics discovery approach, Sarwal and colleagues provided insights into the broad array of autoantibodies developed following renal allograft rejection 34, 35 . Some of these autoantibodies were capable of activating endothelial cells in vitro, causing upregulation of HLA class I, E-selectin and ICAM1 expression 36 . Notably, despite generating autoantibodies following transplantation, the majority of patients did not experience rejection or graft dysfunction. This finding suggests that the pathogenicity of the autoantibodies depends on other factors such as ligand expression, ischaemic injury and/or the state of inflammation within the microenvironment of the allograft. The expression of autoantigens on the endothelium can vary widely depending on their anatomical location, vessel type and inflammatory milieu, which might pose challenges to ascribe clinical relevance to non-HLA autoantibodies 34 . This finding underscores the importance of identifying the nature of the autoantibody ligands on the cells of the allograft to gain mechanistic insight into their pathogenesis. In this Review, we focus on the clinical relevance of a selected group of well-characterized autoantibodies and discuss current theories concerning their pathogenesis in transplantation.
Angiotensin type 1 receptor
Clinical studies in renal transplantation. Angiotensin type 1 receptor (AT1R) is a G-protein coupled receptor that is expressed at the endothelial cell surface, binds to angiotensin II and regulates water-salt balance and blood pressure 37 . Hyperactivity of AT1R causes hypertension, vasoconstriction and vascular smooth muscle migration and proliferation 38 . Antibodies to AT1R were first implicated in pre-eclampsia leading to maternal and fetal mortality and morbidity 39 . In renal transplantation, elevated levels of AT1R antibodies were first reported in transplant recipients with severe steroid-refractory vascular rejection and malignant hypertension in the absence of HLA-DSAs 33 (TABLE 1) . In this study, 13 recipients had DSAs whereas the remaining 20 were HLA-DSA negative. Among those without DSAs, 16 recipients tested positive for AT1R antibodies and presented with vascular injury and malignant hypertension. Even though the AT1R antibodies were IgG1 and IgG3, graft biopsy samples from anti-AT1R-positive patients with vascular rejection did not show evidence of complement deposition. Instead the samples displayed increased expression of tissue factor, which was reduced following treatment with the angiotensin II receptor antagonist losartan. Treatment of AT1R antibody positive patients with a combination of plasmapheresis, intravenous immunoglobulin (IVIG), and losartan resulted in significantly improved allograft survival compared to outcomes for patients who received standard anti-rejection therapy. These results indicate that agonistic antibodies that target AT1R can mediate vascular injury.
Subsequent studies confirmed these initial findings and showed that AT1R antibodies correlated with an increased incidence of AMR and inferior graft survival 29, 30, 32, [40] [41] [42] [43] [44] [45] [46] (TABLE 1) . For example, a strong correlation between AT1R antibody and a diagnosis of AMR was identified in a cohort of 97 kidney transplant recipients who did not have HLA or MHC class I-related chain A (MICA)-DSAs 30 . The researchers observed a relationship between antibody strength and AMR as six of the seven patients diagnosed with AMR had high levels of AT1R antibody (>17 U/ml) both before transplantation and at the time of rejection, whereas none of the nine patients diagnosed with acute cellular rejection (ACR) had AT1R antibodies at these time points. Notably, only one of six AT1R-positive recipients with AMR had C4d staining in their biopsy sample, again suggesting that complement-independent mechanisms contributed to graft injury.
Key points
• Humoral immunity to self-antigens expressed on the allograft is associated with rejection and reduced long-term renal allograft survival • Autoantibodies can mediate graft damage via complement-dependent and complement-independent pathways. • Compelling experimental data suggest that autoantibodies are generated through multiple mechanisms, including presentation of donor-derived extracellular vesicles and apoptotic bodies by host antigen presenting cells • IL-17 and type 17 T helper (T H 17) cell pathways might have a central role in autoantibody production in the setting of allotransplantation through development of tertiary lymphoid tissue (TLT) • TLT promotes B-cell survival and immunoglobulin isotype class switching • More investigation is required to elucidate the pathogenesis of autoantibodies and to develop targeted therapeutic strategies to prevent acute and chronic antibody-mediated rejection Giral et al. showed that >45% of 599 kidney transplant recipients had pretransplantation AT1R antibodies >10 U/ml (REF. 40 ). AT1R autoantibody positivity was associated with a higher risk of acute rejection within the first 4 months after transplantation and a 2.6-fold higher risk of graft failure beyond 3 years posttransplantation, suggesting that AT1R autoantibodies might affect long-term graft survival 40 . Pre-transplantation and post-transplantation AT1R antibodies were studied in 351 consecutive kidney transplant recipients using a cut-off value of 15 U/ml (REF. 44 ). In this study 35 patients were positive for AT1R antibodies before transplantation but became negative for these antibodies after transplantation with no impact on graft survival. By contrast, 12 of 25 patients (48%) with persistent pretransplantation and post-transplantation AT1R antibodies, and seven of 11 patients (64%) who developed de novo AT1R antibodies following transplantation lost their grafts. Furthermore, patients who were positive for both AT1R antibody and HLA-DSA had lower graft survival than those with HLA-DSAs alone, suggesting a synergistic effect of these autoantibodies 44 . The prevalence of pretransplantation AT1R antibody reported across these studies was high, but varied widely from 17% to 59%. A possible explanation for this variation is the use of differing methods for AT1R antibody detection or different cut-off values for determining positive or negative results.
Recurrence of focal segmental glomerulosclerosis (FSGS) after kidney transplantation causes accelerated allograft loss in approximately 30% of transplant recipients [47] [48] [49] [50] . The hallmark of FSGS is podocyte damage resulting in proteinuria and loss of graft function. . Autoantibodies to AT1R were reported in a transplant recipient diagnosed with AMR and FSGS with severe podocyte effacement 52 . Depletion of AT1R antibodies by plasma exchange combined with losartan therapy ameliorated AMR and reduced podocyte injury in this patient. The presence of pretransplantation AT1R antibodies was also assessed in a cohort of 28 renal transplant recipients with a history of idiopathic FSGS. Although no differences were found in pretransplantation AT1R antibody levels between patients with FSGS and a control group of patients with poly cystic kidney disease, significantly higher levels of AT1R antibodies were observed in transplant recipients with FSGS recurrence 53 . Using an integrative bioinformatics approach on high density protoarrays, a panel of auto antibodies were identified as clinically relevant predictors of FSGS recurrence after transplantation 54 . Mechanistic studies suggest that the patient-derived autoantibody to CD40 synergizes with the soluble urokinase receptor to elicit podocyte injury. These studies underscore the clinical importance of AT1R autoantibodies in renal transplant outcome and support the feasibility of developing an autoantibody panel that might serve as a biomarker for risk of FSGS recurrence.
Clinical studies in heart transplantation. Increased pretransplantation levels of AT1R antibodies are associated with heart transplant ACR and AMR as well as early onset of microvasculopathy 55 . A study showed that elevated pretransplantation AT1R antibody levels alone were not associated with an increased risk of rejection, but when both HLA-DSA and AT1R antibodies were present, the risk of AMR and ACR increased significantly, suggesting a synergism between AT1R and HLA antibodies in promoting rejection 56 . Elevated AT1R antibody levels were also reported in patients with a left ventricular assist device (LVAD) as a bridge to transplantation. Over 60% of heart transplant candidates who were AT1R negative before LVAD implantation developed de novo AT1R anti bodies after the procedure independent of blood product usage 57 . Development of AT1R antibodies post-LVAD implantation did not affect the incidence of rejection or transplant survival. The mechanism by which LVADs promote autoantibody production is unknown and research is needed to determine if these devices have unique immuno logic properties that lead to the formation of de novo autoantibodies, or if they elicit inflammation that leads to stimulation of existing memory B cells.
Mechanisms of injury.
Although AT1R antibodies that have been implicated in renal rejection have been identified as IgG1 and IgG3 isotypes, C4d deposition has only been detected in a subset of patients, suggesting that the pathogenic mechanisms of these antibodies involves complement-independent pathways 19, 29, 30, 33 . Indeed, Dragun et al. showed that binding of antibodies to AT1R mimicked the action of angiotensin II and triggered phosphorylation of ERK kinase and activation of the transcription factors AP-1 and NF-κB in endothelial and smooth muscle cells 33 . Renal biopsy specimens from transplant recipients with AT1R-mediated rejection also had increased tissue factor expression and thrombotic occlusions 33 . These occlusions were lessened following treatment with losartan and this effect was accompanied by improved renal function and graft outcome. The effects of AT1R antibodies were recapitulated in a rat transplant model in which passive transfer of agonistic AT1R antibodies caused hypertension and induced vascular changes in the renal transplant including endarteritis and intravascular infiltrates 33 . Together, these clinical and experimental data are consistent with the hypothesis that binding of autoantibody to AT1R contributes to rejection by mimicking the action of angiotensin II.
Although angiotensin II binds to several sites in the extracellular loops and transmembrane helices of AT1R 58 , AT1R antibodies that are implicated in renal allograft rejection have been mapped to the AFJYESQ and ENTNIT epitopes present in the second extracellular loop (ECL2) of AT1R 33 . Molecular dynamics simulations in rat models have shown that the ECL2 has an important role in the conformation of AT1R and consequently different functional states of the receptor 59, 60 . ECL2 conformation differs between the angiotensin II-bound and losartan-bound states that affect AT1R activation 61, 62 , and AT1R antibodies directed toward ECL2 can stabilize the receptor in a permanently activated state 63 . In line with this finding, the time course of vasoconstriction caused by AT1R antibodies in a human fetoplacental pre-eclamptic model was significantly longer in duration than that induced by angiotensin II 64 . As mentioned above, the presence of AT1R autoantibodies before renal transplantation is a risk factor for vascular rejection and malignant hypertension. Not all renal recipients with AT1R antibodies reject their grafts, however, indicating that additional cofactors or environmental conditions might be needed to promote rejection. For example, in a rat model of ischaemiareperfusion injury (IRI), AT1R antibodies mediate renal vascular contraction only under ischaemic conditions 65 . Similarly, AT1R antibodies isolated in sera from patients with HLA-DSA negative vascular rejection induced severe vasoconstriction in arteries of the renal allograft, but not in native arteries 65 . These results support the concept that IRI-mediated damage of the endothelium modulates AT1R expression and/or its conformation to facilitate interactions with AT1R antibodies. These findings were corroborated by studies showing that IRI can lead to the unmasking of neo-epitopes that, once exposed, can serve as a target of natural antibodies 66, 67 .
Perlecan
Clinical studies in renal transplantation. Perlecan -a large heparan sulfate proteoglycan -is a major component of the vessel wall. The C-terminal domain of perlecan, endorepellin, is best known for its anti-angiogenic properties 68 and contains three laminin-like globular (LG) domains separated by two sets of epidermal growth factor (EGF)-like repeats. Most of the antiangiogenic activity of endorepellin resides in the LG3 sub domain. Apoptotic endothelial cells liberate cathepsin-L, which cleaves the LG3 domain from the C-terminal fragment of perlecan 69 . Studies have shown increased serum LG3 levels in renal transplant recipients with immune-mediated vascular injury and renal dysfunction [70] [71] [72] (TABLE 2) . In a retrospective casecontrol study, serum LG3 levels were significantly higher in renal transplant recipients diagnosed with Banff grade II or III acute vascular rejection than in those with Banff grade I acute tubulointerstitial rejection or normal graft function 72 . Furthermore, vascular rejection and elevated LG3 levels were associated with heightened neointima formation. These data identify LG3 as a regulator of vascular remodelling.
An important question is whether or not LG3 also behaves as a neoantigen capable of driving the production of LG3 antibodies that can enhance the process of chronic rejection. Cardinal et al. reported that pretransplantation and post-transplantation levels of LG3 antibodies of the IgG1 and IgG3 isotypes were significantly higher in renal transplant recipients with acute vascular rejection than in those without evidence of rejection 70 . Levels of circulating LG3 sampled at the same time as the LG3 antibodies showed a concomitant increase. Moreover, higher pretransplantation levels of LG3 antibodies identified recipients at risk of vascular rejection. Neither pretransplantation HLA-DSAs alone nor post-transplantation LG3 antibodies alone reduced renal allograft survival in patients diagnosed with vascular rejection, but patients with pretransplantation DSAs and strong post-transplantation LG3 antibodies had significantly reduced 1-year graft survival. These results suggest that similar to AT1R antibodies, HLA-DSAs and LG3 autoantibodies can synergize to elicit endothelial cell and graft damage.
Mechanisms of injury.
The current paradigm of perlecanmediated graft injury considers two different, but interdependent mechanisms whereby bioactive forms of perlecan cause vascular injury and neointimal formation directly by promoting migration of donor vascular smooth muscle and/or recipient-derived mesenchymal cells, and/or elicit humoral immune responses that accelerate immune-mediated vascular injury and remodelling. Studies by the Hebert group have provided supporting evidence for both models. First, they showed that passive transfer of anti-LG3 IgG in a murine model of vascular rejection significantly increased infiltration of T cells and natural killer cells, C4d deposition and obliterative vascular remodelling in recipients of ischaemic aortic allografts, but not in adjacent non-ischaemic native aortas 70 . Second, they showed that escalating serum LG3 levels in murine aortic allograft recipients significantly increased neointima formation 70 . To address the question of how LG3 contributes directly to vascular remodelling, recombinant LG3 was administered to mice transplanted with aortic allografts. Injection of LG3 enhanced smooth muscle cell migration and neointima formation via an ERK dependent pathway 72 . Moreover, in addition to cells of donor origin, injection of LG3 promoted the accumulation of recipient-derived mesenchymal stem cells (MSCs) and smooth muscle cells into the sites of neointima formation, which was dependent upon MSC expression of α2β1 integrin 73 . Together these findings suggest that LG3 causes vascular injury and neointimal formation by stimulating autoantibody production and/or by promoting the migration of vascular smooth muscle cells and/or MSCs.
Collagen
Clinical studies in lung transplantation. The clinical relevance of collagen autoantibodies has mainly been assessed in the setting of lung transplantation (TABLE 3) . Collagen V is present on airway epithelial cells and its expression increases following immune-mediated injury and/or IRI 74, 75 . Graft injury is thought to induce the expression of matrix metalloproteinases that modify collagen and release collagen fragments that serve as a major target for autoantibody production 76 . Posttransplantation development of collagen V antibody is associated with the development of bronchiolitis obliterans syndrome (BOS) in lung transplant recipients [76] [77] [78] [79] . A trans vivo delayed type hypersensitivity assay showed that a collagen V-specific cellular response in these patients was dependent on both CD4 T cells and monocytes that required IL-17, TNF and IL-1β 77 . Patients with idiopathic pulmonary fibrosis and cystic fibrosis reportedly have the highest prevalence of antibodies to collagen V and Kα-tubulin and are at increased risk of developing primary graft dysfunction, HLA-DSAs and BOS 79 .
Clinical studies in renal transplantation. Late renal allograft failure owing to chronic allograft nephropathy is one of the major challenges to the long-term success of renal transplantation. Transplant glomerulopathy is characterized by duplication of the glomerular basement membrane and is associated with chronic renal allograft rejection. Development of autoantibodies to collagen IV and fibronectin has been reported in renal transplant recipients diagnosed with transplant glomerulopathy 80 . These patients displayed increased collagen IV-specific and fibronectin-specific 
CD4
+ T cells that secreted IFNγ and IL-17, as well as a reduction in IL-10 levels, implicating collagen IV in the pathogenesis of chronic rejection 80 .
Clinical studies in heart transplantation. Collagen autoantibodies have also been implicated in heart transplant rejection. The development of HLA-DSAs in recipients diagnosed with AMR correlated with the development of autoantibodies to collagen V 81 . Production of DSAs to HLA and autoantibodies to collagen V was accompanied by increased frequencies of collagen V-specific type 17 T helper (T H 17) cells that secreted IL-17 and an increased risk of coronary artery vasculopathy.
Mechanisms of injury. Administration of collagen V-specific CD4
+ T cells or antibodies to collagen V can induce BOS in experimental models of lung transplantation 77 . The role of IL-17-dependent cell-mediated immunity to collagen V in the development of BOS was first demonstrated in a study of lung transplant recipients who were monitored over a period of 7 years following transplantation. Strong collagen V responses correlated with both the frequency and severity of BOS 77 .
An orthotopic rat lung isograft model and adoptive transfer experiments were utilized to demonstrate that T H 17-mediated immunity to collagen V can induce transplant vasculopathy in the absence of alloimmunity. Immunization of rats with collagen V induced upregulation of IL-17 and IL-23 mRNA expression in T cells and adoptive transfer of these T H 17 cells caused development of BOS lesions in lung isografts 77 . The causal role of T H 17 cells in acute allograft rejection was further confirmed by adoptive transfer of CD4 + collagen V-specific T H 17 cells into rat lung isografts 82 . Treatment with neutralizing IL-17 prevented BOS in orthotopic lung transplantation and chronic corneal allograft rejection in experimental mouse models 83, 84 . Furthermore, adoptive transfer of CD4 + collagen V-specific regulatory T cells successfully blocked T H 17-mediated acute lung transplant rejection in a rat model 82 . The mechanism for this T H 17 suppression is consistent with an induction of tolerance to collagen V, suggesting that targeting T H 17 development might lead to improved long-term outcomes in lung transplantation.
Transfer of anti-collagen V antibodies to rat recipients of lung isografts induced primary graft dysfunction, a leading cause of early mortality in lung transplantation and a major risk factor for BOS 74 . The adoptively transferred anti-collagen V antibodies were capable of inducing airway epithelial cell cytotoxicity in the lung isografts, implicating complement as a mechanism of graft injury. Intrabronchial administration of anti-MHC class I antibodies to IL-17a-knockout C57BL/6 mice induced a marked reduction in cellular infiltration, decreased fibrosis, and a substantial (2.17-fold) decrease in collagen V antibody levels in comparison to wild-type mice 85 . These findings indicate that IL-17A and IL-17F secreted by CD4
+ T H 17 cells specific to lung self-antigens are critical mediators of autoimmunity in the pathogenesis of BOS.
Autoantibody production in transplantation
Autoantibody production in the transplant setting depends on multiple factors. Graft damage mediated through IRI, alloimmunity and chronic inflammation can cause intracellular proteins to be expressed on the surface of apoptotic cells, raising the possibility that these cells act as autoantigen reservoirs 86 .
The autoantigens can be subsequently presented to autoreactive T cells and B cells either by recipient or donor antigen presenting cells (APCs), in the context of extracellular vesicles or in tertiary lymphoid tissue (TLT; an ectopic accumulation of lymphoid cells with characteristics similar to that of a germinal centre within a secondary lymphoid organ). Improved understanding of the mechanisms that underlie autoantibody production could lead to the identification of new therapeutic strategies to prevent or control transplant rejection and aberrant vascular remodelling.
Ischaemia-reperfusion injury. Organ transplantation inevitably involves varying levels of surgical trauma, tissue damage and IRI, all of which can elicit innate inflammatory responses that contribute to the generation of alloimmune and autoimmune responses to the graft. Although the immune system has a number of checkpoints to preserve tolerance to self-antigens, including central and peripheral tolerance, defects in these checkpoints coupled with the constant presence of autoantigen leads to chronic inflammation 87 . IRI is a complex pathophysiological process that involves the generation of reactive oxygen species, complement activation, coagulation, endothelial activation and leukocyte recruitment (FIG. 1) . The tissue damage caused by IRI can lead to acute kidney injury and delayed graft function, which can impair graft survival 88 . Apoptosis and necrosis caused by IRI results in the release of damage associated molecular patterns (DAMPs) including self-nucleic acids, histones, and high mobility group protein B1. DAMPs can interact with pattern recognition receptors including Toll-like receptor (TLR) 2 and TLR4 expressed on myeloid cells 89, 90 , dendritic cells 89 , vascular endothelial cells 91, 92 , and tubular epithelial cells 93 . Ligation of TLRs results in the recruitment of MYD88 and the production of NF-κB. This process in turn causes downstream production of proinflammatory cytokines, including IL-1β, IL-6, and TNF, which promote the activation of adaptive immune responses that can exacerbate allograft damage and exposure to autoantigens 93 . Several studies have demonstrated that IRI is sufficient to induce an autoimmune response in the absence of alloimmunity 70, 75 . For example, adoptive transfer of collagen V-reactive lymphocytes to Wistar Kyoto rats induced grade II rejection in fresh isografts and collagen V expression (detected using immunhistochemistry) in fresh and well-healed isografts, but not in native lungs 75 . These data indicate that IRI predisposes to anti-collagen-V-mediated pathology. TLR4 expression was also elevated in deceased donor kidney transplants, and loss-of-function mutations in TLR4 were associated with lower intragraft expression of proinflammatory genes such as TNF and MCP-1 (REF. 93 ). IRI, natural antibodies, HLA-DSAs and complement can damage the vascular endothelium, leading to release of autoantigens from necrotic and apoptotic cells (FIG. 1) . Autoantigens such as vimentin, perlecan, and collagen V released from the injured allograft are processed and presented to autoreactive T cells by APCs recruited during IRI 70, 94, 95 . Circulating B cells bind these autoantigens and become activated by autoreactive T cells, resulting in the secretion of autoantibodies. In addition, complement activation can potentiate autoantibody production in the transplant setting.
In a murine chronic lung transplant model, C3a increased IL-17 production by collagen V-reactive T cells, suggesting an important role of complement in the development of autoantibody responses 96 . In addition, C3 can bind directly to self-antigens leading to an efficient retention of antigens in the areas of B cells in lymphoid tissue and a reduced threshold for B-cell stimulation by these autoantigens 97, 98 . Mice lacking complement fail to initiate high-affinity IgG production against MHC in skin grafts 99 . The mechanism involves antigen-bound C3dg, an iC3b cleavage product, binding to complement receptor 2 (CD21) on B cells and lowering the threshold for B-cell activation 98 . Work from several groups has uncovered a novel role for complement spilt products in T cell and APC activation, resulting in signals that induce T-cell proliferation and APC upregulation of co-stimulatory molecules and cytokines 100 .
Interplay between alloimmunity and autoimmunity. Alloimmune responses to the transplanted organ or tissue occur through direct, indirect and semi-direct allorecognition pathways 101 . Once initiated, the indirect alloimmune response can spread to additional determinants within the primary target antigen, in a process termed intramolecular epitope spreading 102, 103 . This expansion of alloreactive T cells to donor-derived MHC antigens via the indirect allorecognition pathway is associated with chronic rejection and linked to the generation of DSAs [103] [104] [105] [106] . Similarly, the indirect recognition pathway can also promote the development of autoimmune T and B cells that contribute to the rejection process 107 . The indirect alloresponse triggers autoimmunity after transplantation presumably via antigen mimicry between autoantigen peptides and donor MHC peptides 108 . Several studies have shown that auto reactive proinflammatory T cells specific for collagen V and cardiac myosin are detected after lung and heart transplantation, respectively. Clonal expansion of these T cells occurs only after an alloresponse, and once stimulated they can induce rejection of allogeneic transplants 77, 81, 109, 110 . Alternatively the tissue damage caused by the alloresponse to donor HLA antigens can cause the release of sequestered autoantigens, resulting in the presentation of cryptic self-determinants and thereby triggering an autoimmune process at the graft site.
Once autoreactive T cells are generated, chronic stimulation of these cells can lead to epitope spreading, which has been reported to contribute to the generation of autoantibodies 111 . For example, sequential analysis of antibody development against collagen V following lung transplantation demonstrated that patients initially develop antibodies to both α1(V) and α2(V) of collagen V, yet at the time of BOS diagnosis, the antibodies had shifted entirely to α1(V), demonstrating the importance of epitope spreading in the development of this disease 76 . A more refined epitope analysis of collagen V-specific CD4 + T H 17 cells in patients with BOS showed HLA-restricted epitope binding of α1(V) in association with the HLA-DR15 genotype 112 . Interestingly, an HLA-DR15 negative recipient who received a transplant from a HLA-DR15 positive donor also responded to DR15-restricted collagen V epitopes after lung transplantation, suggesting determinant spreading from recipient DR-restricted epitopes to donor HLA-DR restricted epitopes 112, 113 . During progression of chronic rejection in heart and kidney transplant recipients, 'inter-molecular epitope spreading' has been described for indirect pathway responses to donor alloantigen 114 . It is plausible, therefore, that acquisition of a donor class II-restricted response to self-antigens is yet another mechanism that contributes to chronic rejection. This hypothesis has important clinical implications for the development of autoimmunity post-transplantation and underscores the importance of identifying the specific autoantigens and their HLArestricted epitopes. Ultimately this information might guide the allocation of lung transplants and the development of therapeutic strategies to prevent chronic rejection.
Extracellular vesicles.
Cell-to-cell communication through extracellular vesicles is increasingly recognized as a mechanism that elicits autoimmune and alloimmune responses 115, 116 . Depending on their cellular source, extracellular vesicles contain mRNAs, mi cro RNAs, DNA, proteins, lipids and carbohydrates, and can positively or negatively modulate immune responses 116 . Based on their biogenesis, extracellular vesicles can be categorized into three classes -exosomes, microparticles and apoptotic bodies -all of which contain numerous autoantigens. Extracellular vesicles released by APCs also carry surface MHC class I and II molecules plus bound peptides that can activate T cells [117] [118] [119] [120] [121] [122] . Although high concentrations of exosomes can directly activate T cells 118, 119 , the activatory effect of this type of antigen presentation is much weaker than that of antigen presentation by professional APCs owing to the lack of co-stimulatory molecules (FIG. 2) . By contrast, exosomes efficiently activate T cells when they interact with dendritic cells 117, 120 . In mouse models of cardiac and skin transplantation, internalization of host-derived exosomes by recipient splenic dendritic cells led to activation of anti-donor CD4 T cells by the indirect pathway of allorecognition 117 . In addition, donor autoantigen-MHC complexes from internalized extracellular vesicles can be recycled and presented as intact molecules on the surface of recipient APCs to recipient T cells through the process of cross-dressing (FIG. 2) 116 . The role of apoptotic exosome-like vesicles in regulating the production of autoantibodies was demonstrated 123 . This study showed that high levels of the immunogenic LG3 fragment of perlecan were present in apoptotic exosome-like vesicles, but not in apoptotic bodies. Moreover, injection of apoptotic exosome-like vesicles in an in vivo murine aorta transplant model not only induced the production of LG3 antibodies, but also increased the severity of rejection.
T H 17 cells and tertiary lymphoid tissue. T H 17 cells are the major producers of IL-17 and have been implicated in many autoimmune diseases 124, 125 . T H 17 cells activated by TGF-β and IL-6 are potent inducers of leuko cyte recruitment and mediate protective responses to foreign pathogens, whereas T H 17 cells activated by IL-23 promote chronic tissue inflammation and autoimmunity. A large body of data demonstrates the importance of IL-17 in solid organ transplant rejection and the generation of autoimmune responses, particularly in lung allograft rejection 55, 76, 77, 79, 81, 112 . Early lung allograft rejection caused by T H 17 cells can be attributed to recruitment of neutrophils into the graft (FIG. 3) . For example, intradermal injection of IL-17 into human skin grafts transplanted onto mice with severe combined immunodeficiency induced neutrophil infiltration 126 . In addition, IL-17-knockout mice showed delayed neutrophil infiltration after cardiac allograft transplantation 127 . The development of TLT has been reported in chronic allograft rejection of kidney [128] [129] [130] [131] , lung 132 and heart transplants 131, 133 . TLT arises in the setting of chronic inflammation through a process called lymphoid neogenesis (FIG. 3) . In certain autoimmune diseases TLT supports the proliferation and maturation of autoreactive B cells 134 . Hsu and colleagues demonstrated that T H 17 cells that secrete IL-17 orchestrated the spontaneous formation of autoreactive germinal centres in a mouse model of autoimmunity 135 . Consistent with these findings, transfer of T H 17 cells into T-cell-deficient mice induced a pronounced autoantibody response with preferential isotype class switching as well as the formation of germinal centres 124 . Isotype class switching was dependent on the production of IL-21 by T H 17 cells 124 . T H 17 cells have a greater capacity to provide cognate B cell help than do T H 1 cell populations as a result of their higher clonal expansion, persistence in the B cell follicle and/or the expression of inducible T-cell costimulator (ICOS), which is important for T-cell-dependent antibody production. IL-17 has also been demonstrated to promote TLT formation in the mouse lung by upregulating the expression of CXCL13 and CCL19, which have a central role in T-cell and B-cell recruitment and TLT organization 136, 137 . Autoreactive B cells might escape apoptosis and negative selection in TLT due to sustained local production of BAFF and IL-21, which promote B-cell survival 138 . Furthermore under proinflammatory conditions, TLT is constantly fed neo-antigens released by tissue injury and trapped by defective lymphatic drainage, leading to the production of pathogenic autoantibodies 139 . Collectively, these data underscore the important role of T H 17 cells in B-cell differentiation and antibody production.
Conclusions and future perspectives
Mounting evidence supports the importance of immunity to self-antigens in both acute and chronic rejection of solid-organ transplants. Autoantibody production might occur via several mechanisms, including the inefficient clearance of extracellular vesicles, particularly apoptotic bodies, crossreactivity between self and foreign antigens, and interplay between innate and adaptive immunity.
The patterns of clinical presentation and response to desensitization therapy of non-HLA antibodies have not been clearly established. Current treatment strategies for AMR caused by autoantibodies are similar to those used for AMR caused by HLA antibodies, including antibody depletion 140 , B-cell depletion 141 , IVIG 142 proteosome inhibitors 143, 144 and complement inhibitors 145, 146 . However, whether these regimens are effective either alone or in combination is not clear. This issue was highlighted in a case report of renal artery thrombosis, accelerated rejection and graft loss associated with AT1R antibody that was refractory to AT1R blockade, plasmapheresis, IVIG, cortico steroids and eculizumab 32 . A need clearly exists for further investigation into the pathogenic mechanisms of autoanti bodies and the identification of more effective therapies. A potential candidate is the IL-6 inhibitor tocilizumab, which reduced the production of HLA-DSAs in desensitization-resistant kidney transplant recipients in a small pilot study 147 . Therapeutic strategies targeting IL-17 pathways, micro RNA regulation [148] [149] [150] and exosomes might also become viable options to treat autoantibody-mediated AMR and improve graft survival.
Incomplete knowledge of the autoantigens that elicit immune responses during transplantation hampers the diagnosis and treatment of AMR. Modern genomics and proteomics platforms provide extraordinary new tools to examine antibody repertoires 34, 35, 151, 152 , and continued efforts to define their targets is warranted to understand the mechanisms and pathogenesis of autoantibodies and to develop strategies to improve long-term transplant outcomes. 
